Survival after moderate HFRT in patients with high-risk prostate cancer was a secondary outcome of the randomized phase 3 Prostate Cancer Study 5 trial.
RaySearch Laboratories AB (publ) is proud to announce that the number of radiotherapy centers in China using RayStation®* for treatment planning now has passed 100. In terms of number of centers, ...
GenesisCare is the UK's leading independent cancer care provider, operating 14 specialist outpatient cancer centers. This order signifies the plan to fully replace its current Pinnacle radiotherapy ...
StockNews.com assumed coverage on shares of Concord Medical Services (NYSE:CCM – Free Report) in a research report released on Monday. The brokerage issued a sell rating on the stock. Concord Medical ...